Korean J Hematol 2007; 42(2):
Published online June 30, 2007
https://doi.org/10.5045/kjh.2007.42.2.129
© The Korean Society of Hematology
김동훈, 손진희, 김민경, 이경분, 강성희, 채승완
성균관대학교 의과대학, 강북삼성병원 병리과
Background:
The molecular mechanisms that are responsible for the initiation and progression of diffuse large B-cell lymphoma are largely unknown. p16 is an inhibitor of cyclin-dependent kinase and its inactivation by methylation has been reported as a major tumorigenic mechanism in malignant tumors. The aim of this study was to analyze the correlation between the clinical data and the p16 protein expression in diffuse large B-cell lymphomas.
Methods:
Tumor samples were obtained from 62 patients who were suffering with diffuse large B-cell lymphoma. To investigate the role of p16 in the pathogenesis and progression of diffuse large B-cell lymphoma, 62 cases of diffuse large B-cell lymphoma were examined for their expression of p16 via performing immunohistochemistry. The correlation of the p16 expression with the various clinicopathologic findings was also analyzed.
Results:
p16 was expressed in all the cases of reactive lymphoid hyperplasia (100%) and in 40 cases (64.5%) out of the 62 cases of diffuse large B-cell lymphoma that we studied. The expression rate of p16 was 31.8% in the high risk group and 82.5% in the low risk group of diffuse large B-cell lymphoma. The expression rate of p16 in the fatal cases was 12.5%. For our results, the loss of a p16 expression in diffuse large B-cell lymphoma was noted, and especially in the high risk group (P=0.04).
Conclusion:
The loss of p16 appeared to be involved in the genesis or progression of diffuse large B-cell lymphoma. In addition, the loss of the p16 expression may play important roles for patients' progression into the high risk group and it may cause more mortality for those patients with diffuse large B-cell lymphoma. Deranged expressions and loss of the p16 expression may play an important role in the pathogenesis of diffuse large B-cell lymphoma.
Keywords Malignant lymphoma, Diffuse large B-cell lymphoma, p16
Korean J Hematol 2007; 42(2): 129-135
Published online June 30, 2007 https://doi.org/10.5045/kjh.2007.42.2.129
Copyright © The Korean Society of Hematology.
김동훈, 손진희, 김민경, 이경분, 강성희, 채승완
성균관대학교 의과대학, 강북삼성병원 병리과
Dong Hoon Kim, Jin Hee Sohn, Min Kyung Kim, Kyoung Bun Lee, Sung Hee Kang, Seoung Wan Chae
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Korea
Background:
The molecular mechanisms that are responsible for the initiation and progression of diffuse large B-cell lymphoma are largely unknown. p16 is an inhibitor of cyclin-dependent kinase and its inactivation by methylation has been reported as a major tumorigenic mechanism in malignant tumors. The aim of this study was to analyze the correlation between the clinical data and the p16 protein expression in diffuse large B-cell lymphomas.
Methods:
Tumor samples were obtained from 62 patients who were suffering with diffuse large B-cell lymphoma. To investigate the role of p16 in the pathogenesis and progression of diffuse large B-cell lymphoma, 62 cases of diffuse large B-cell lymphoma were examined for their expression of p16 via performing immunohistochemistry. The correlation of the p16 expression with the various clinicopathologic findings was also analyzed.
Results:
p16 was expressed in all the cases of reactive lymphoid hyperplasia (100%) and in 40 cases (64.5%) out of the 62 cases of diffuse large B-cell lymphoma that we studied. The expression rate of p16 was 31.8% in the high risk group and 82.5% in the low risk group of diffuse large B-cell lymphoma. The expression rate of p16 in the fatal cases was 12.5%. For our results, the loss of a p16 expression in diffuse large B-cell lymphoma was noted, and especially in the high risk group (P=0.04).
Conclusion:
The loss of p16 appeared to be involved in the genesis or progression of diffuse large B-cell lymphoma. In addition, the loss of the p16 expression may play important roles for patients' progression into the high risk group and it may cause more mortality for those patients with diffuse large B-cell lymphoma. Deranged expressions and loss of the p16 expression may play an important role in the pathogenesis of diffuse large B-cell lymphoma.
Keywords: Malignant lymphoma, Diffuse large B-cell lymphoma, p16
Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun
Blood Res 2023; 58(4): 187-193Ufuk Demirci, Meltem Kurt Yüksel, Hakkı Onur Kırkızlar, Elif Birtaş Ateşoğlu, Özgür Mehtap, Ozan Salim, Ahmet Muzaffer Demir, Olga Meltem Akay
Blood Res 2023; 58(2): 99-104Jihoon Kang, Shinkyo Yoon, and Cheolwon Suh
Blood Res 2017; 52(4): 276-284